TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
24 hedge funds and large institutions have $903K invested in TRACON Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
14% more funds holding
Funds holding: 21 → 24 (+3)
46% less capital invested
Capital invested by funds: $1.66M → $903K (-$754K)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$72.8K |
| 2 |
Squarepoint
New York
|
+$72.5K |
| 3 |
Millennium Management
New York
|
+$33.7K |
| 4 |
GS
GTS Securities
New York
|
+$2.78K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$141 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$848K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$62.8K |
| 3 |
Renaissance Technologies
New York
|
-$6.42K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.82K |
| 5 |
BlackRock
New York
|
-$1.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | -$4 | -1 | Closed |
|
TCON Hedge Fund Activity: Q4 2023 in Review
24 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2023, worth a combined $903K — down 46% from $1.66M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TCON positions and 4 closed out — a net gain of 3 holders — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $72.8K. The largest seller was Opaleye Management, exiting entirely with an estimated $848K sold.
- 24 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $903K of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2023, down 46% quarter-over-quarter.
- 7 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 4 closed out, a net change of +3 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Acadian Asset Management, an estimated $72.8K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was Opaleye Management, an estimated $848K sold.
Based on aggregated 13F filings for Q4 2023.